LOGIN  |  REGISTER

Latest Peer Reviewed News

Manuscript Published on Multiorgan Failure Patients Treated with SeaStar Medical’s Selective Cytopheretic Device Who Achieved Transplant Eligibility

May 22
Last Trade: 0.37 -0.0047 -1.24

SCD’s ability to improve clinical status of four critically ill pediatric and adult patients across multiple clinical conditions published in Transplantation Direct DENVER, May 22, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the publication of a...Read more


Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules

May 21
Last Trade: 139.40 -1.11 -0.79

SAN DIEGO, May 21, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of data from a post hoc analysis of the Phase 3 KINECT®-4 study of INGREZZA® (valbenazine) capsules in the Journal of Clinical Psychopharmacology. The analysis assessed long-term outcomes relevant to the real-world management of tardive dyskinesia (TD) and demonstrated that nearly all study participants met the...Read more


Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery

May 21
Last Trade: 1.26 -0.09 -6.67

Data shows that the Trans-Arterial Micro-Perfusion (TAMP) platform increases intra-arterial pressure, improving drug delivery with 100-fold increase local tissue concentration of the therapy TAMP offers the potential to increase efficacy, improve safety and widen therapeutic window of drugs or other agents LOS ALTOS, Calif. / May 21, 2024 / Business Wire / RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage...Read more


Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other Glial...

May 21
Last Trade: 8.02 0.04 0.50

Healthy transplanted human glial cells replaced diseased glial cells in the brains of human glial chimeric Huntingtin mice Additional proof-of-concept for the advancement of SC379, Sana’s pluripotent stem cell-derived glial progenitor cell product candidate SEATTLE, May 21, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today...Read more


Bionano Genomics Announces Three Publications Demonstrating OGM’s Utility for Cell and Gene Therapy

May 21
Last Trade: 1.07 0.04 3.88

Three peer-reviewed publications collectively illustrate the building support for optical genome mapping (OGM) as a tool for cell and gene therapy development that allows researchers in academic medical centers and biopharmaceutical companies to assess genome integrity in therapeutic cell lines like chimeric antigen receptor-modified T cells (CAR-T), stem cells, and cell lines used for translational research in unraveling genetic causes...Read more


Annovis Announces New Publication in a Peer-Reviewed Journal

May 21
Last Trade: 7.29 0.21 2.97

MALVERN, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the publication of a new article focused on the comparison of pharmacokinetic profiles of Posiphen (or buntanetap) across different species in a peer-reviewed journal Biomolecules as part of the Special Issue: Role of Amyloid...Read more


Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®

May 21
Last Trade: 1.35 -0.01 -0.74

Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic Delivery  Current Clinical Evidence and Physician Experience Support SCS Injection as a Safe and Effective Method for Delivering Retinal and Choroidal Therapeutics  ALPHARETTA, Ga., May 21, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company...Read more


Regeneron Pharmaceuticals: Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine

May 20
Last Trade: 985.02 4.45 0.45

NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD TARRYTOWN, N.Y. and...Read more


Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

May 20
Last Trade: 30.41 -0.80 -2.56

Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan.  These results add to recently published data on ARCT-154 demonstrating superior immunogenicity to Omicron BA 4/5 compared to conventional mRNA COVID-19 vaccine booster and follow-up data demonstrating longer duration of immunity compared to traditional COVID-19 mRNA vaccine booster. KING OF PRUSSIA, Pa. and SAN DIEGO,...Read more


Boston Scientific: MODULAR ATP Study of the mCRM™ System Meets Primary Safety and Efficacy Endpoints

May 18
Last Trade: 75.63 1.25 1.68

Additional data from APPRAISE ATP trial reinforce modular therapy approach with EMBLEM™ Subcutaneous Implantable Defibrillator and EMPOWER™ Leadless Pacemaker MARLBOROUGH, Mass., May 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM™ System,* the first modular cardiac rhythm management (CRM) system that...Read more


Landmark Study Shows CareDx’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies

May 16
Last Trade: 15.94 0.11 0.69

HeartCare Results Effectively Stratified Patients at Highest Risk for Acute Cellular Rejection Cardiologists Performed the Fewest Biopsies After Dual Negative HeartCare Results Compared to Single or Dual Positive Results Two-Year Clinical Outcomes Data Demonstrate Excellent Survival and Allograft Function BRISBANE, Calif. / May 16, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision...Read more


New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer

May 16
Last Trade: 23.16 -0.11 -0.47

Myriad’s Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1 SALT LAKE CITY, May 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that JCO Precision Oncology has published a study showing a clinical cell-cycle risk (CCR) score can accurately predict the benefit of adding androgen...Read more


Soligenix: Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice

May 16
Last Trade: 0.37 0.006 1.67

Published Results Confirm and Extend Response Results from Phase 3 FLASH Study PRINCETON, N.J., May 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the results of its compatibility study evaluating HyBryte™ (synthetic...Read more


Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)

May 15
Last Trade: 1.89 -0.07 -3.66

Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) administered DHE. Self-administered PUR3100 showed improved safety and tolerability relative to IV DHE. Pulmatrix previously received FDA's acceptance of an IND application and a "study may proceed" letter for a Phase 2 study, positioning PUR3100 as Phase 2-ready. BEDFORD, Mass., May 15, 2024...Read more


Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

May 14
Last Trade: 3.47 0.00 0.00

FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that the Journal for ImmunoTherapy of Cancer, a peer-reviewed online journal of the Society for Immunotherapy of Cancer, published data highlighting the potential advantages of...Read more


Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine

May 13
Last Trade: 48.30 -0.68 -1.39

Statistically Significant and Clinically Meaningful Improvements Observed in Primary Efficacy Endpoint and All Secondary Endpoints; Results Consistent Across All Prespecified Subgroups Rapid and Sustained Improvements Observed in Symptoms and Function; No Treatment Interruptions Due to Low LVEF Company to Host Investor Event and Webcast Today at 4:00 PM Western European Summer Time (11:00 AM Eastern Time) SOUTH SAN FRANCISCO,...Read more


Arcutis Biotherapeutics: Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology

May 13
Last Trade: 9.16 0.08 0.88

Eight of nine experts expressed feeling “extremely confident” about prescribing ZORYVE foam to patients of diverse skin and hair types, including individuals with previous hair treatments, based on review of formulation data Crodafos™ CES, used in ZORYVE foam, is suitable for a wide variety of skin and hair types Findings from this formulation review underscore the suitability of ZORYVE foam for use on all affected areas of the body,...Read more


Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology

May 8
Last Trade: 7.21 -0.21 -2.83

Phase 2b ReDUX4 clinical trial indicates improvements in functional, structural, and patient-reported outcomes; findings informed the design and choice of efficacy endpoints in the ongoing Phase 3 clinical trial Topline data for the Phase 3 REACH clinical trial of losmapimod in FSHD expected during 4Q’24 CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage...Read more


Mirum Pharmaceuticals Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC

May 7
Last Trade: 24.55 -0.92 -3.61

Data demonstrate significant benefit across broadest range of genetic PFIC types ever studied Significant improvements observed across multiple parameters including pruritus, serum bile acids, growth and bilirubin FOSTER CITY, Calif. / May 07, 2024 / Business Wire / Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that data from the Phase 3 MARCH-PFIC study evaluating LIVMARLI® (maralixibat) oral solution in patients with...Read more


Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure Medical's ProSense®, Adding to Continued Positive Data Published Globally

May 7
Last Trade: 1.03 -0.01 -0.96

Study published in the peer reviewed journal Breast Cancer Excellent cosmetic outcomes, high degree of patient satisfaction, and improved quality of life post-cryoablation Strategic distribution partner of ProSense® in Japan, Terumo Corporation, expects to submit an application for regulatory clearance for breast cancer in the second half of 202 CAESAREA, Israel, May 7, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq:...Read more


Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone

May 7
Last Trade: 25.52 3.01 13.37

PALO ALTO, Calif. / May 07, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its achievement of surpassing a significant milestone of 500 peer-reviewed publications featuring its technology in esteemed scientific journals. This milestone highlights Guardant Health’s leadership, amassing one of the most robust portfolios of relevant liquid biopsy research studies in the...Read more


Aspira Women’s Health Announces Publication of Two OvaWatch Peer-Reviewed Manuscripts

May 7
Last Trade: 2.29 -0.04 -1.72

AUSTIN, Texas, May 07, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the publication of two peer-reviewed manuscripts. The first manuscript, entitled “Ovarian Cancer Surgical Consideration is Markedly Improved by the Neural Network Powered-MIA3G Multivariate...Read more


Delcath Systems: Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT

May 6
Last Trade: 7.78 -0.07 -0.89

Significantly Higher Overall Response Rate vs Meta-analysis of Historical Controls (36.3% vs. 5.5%) Other Efficacy Endpoints Include a 73.6% Disease Control Rate with a 7.7% Complete Response Rate NEW YORK, May 6, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of results from...Read more


New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer

May 3
Last Trade: 109.51 2.00 1.86

Expanded EBLIS study with up to 12 years of clinical follow-up across all subtypes of breast cancer AUSTIN, Texas / May 03, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to detect recurrence early in...Read more


Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing

May 2
Last Trade: 0.92 -0.01 -1.52

EsoGuard demonstrated unprecedented early precancer detection, including 89% sensitivity at detecting short segment early precancer, the primary target of esophageal precancer testing Publication further strengthens EsoGuard's clinical data supporting ongoing engagement to secure commercial and Medicare payor coverage NEW YORK, May 2, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a...Read more


Senti Biosciences Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)

April 30
Last Trade: 0.34 -0.01 -3.11

Preclinical data demonstrates the potential for improved treatment outcomes and reduced toxicity for patients with AML  Data supports the design of Phase 1 clinical trial of SENTI-202 with patient dosing anticipated in the second quarter of 2024  SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and...Read more


In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy

April 30
Last Trade: 0.16 -0.0014 -0.85

BEDMINSTER, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its oral formulation of the potent antifungal amphotericin B, demonstrated efficacy compared with placebo in treating the pulmonary mucormycosis fungal...Read more


Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome

April 30
Last Trade: 41.16 -0.01 -0.02

REDWOOD CITY, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the publication of the comparison of results from the Company’s Phase 3 placebo-controlled study (C601) and open-label extension study (C602) evaluating investigational, once-daily DCCR (Diazoxide Choline)...Read more


Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

April 30
Last Trade: 1.25 0.01 0.81

30 mg and 45 mg Daily Doses of Vidofludimus Calcium Suppressed Development of Gadolinium-Enhancing Lesions by 78% and 74% Compared to Pooled Placebo at 24 Weeks  Improvements in Serum Neurofilament Light Chain Consistent with Recently Announced Interim Phase 2 CALLIPER Data in Progressive Multiple Sclerosis  Twin Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis and Phase 2 CALLIPER Trial in Progressive Multiple...Read more


Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology

April 29
Last Trade: 36.76 -0.61 -1.63

Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks and 26% at one year of treatment Topline data from ongoing pivotal Phase 3 clinical trial in hypothalamic obesity on track for 2Q 2025 BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives...Read more


Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action 

April 29
Last Trade: 3.81 0.00 0.00

Preclinical data of tetra-specific T cell engager MP0533 demonstrate preferential T cell mediated killing of AML cells, while sparing healthy cells Results highlight MP0533-mediated T-cell activation and tumor regression, as well as cytokine release in AML models without systemic adverse effects Published data build on results previously presented at ASH 2021 and 2022, and support the rationale for the clinical development of MP0533...Read more


Cardio Diagnostics Announces Publication of Study Showing That its PrecisionCHD™ Test Could Save Health Insurers Over $113 Million Annually

April 29
Last Trade: 0.69 -0.01 -2.03

The Peer-Reviewed Publication Demonstrates the Potential Economic Benefits of the PrecisionCHD™ Test for the Detection and Management of Coronary Heart Disease, which is One of the Largest Cost Centers for Public and Private Payers. CHICAGO / Apr 29, 2024 / Business Wire / Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in the next generation of precision cardiovascular medicine technologies that combine proprietary AI...Read more


Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™

April 29
Last Trade: 1.02 -0.03 -2.95

BRAINTREE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today reports that the first phase of the previously announced collaboration with Corewell Health has been completed, which demonstrated the LIBERTY® System's technical capabilities and outlines potential future applications in a range of endovascular interventions. The...Read more


ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease

April 29
Last Trade: 4.31 0.02 0.46

This publication, authored by leading experts in inflammasome-mediated inflammation and neurology at University of Miami Miller School of Medicine, demonstrates that multiple inflammasome triggers (NLRP1 and pyrin) govern the inflammatory response in Alzheimer’s Disease (AD), and that release of inflammasome laden extracellular vesicles (EV) into the blood induce significant inflammation in cardiovascular cells. ZyVersa is developing...Read more


Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab

April 25
Last Trade: 0.81 0.07 9.34

NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced for the first time, quantitative data showing improvement in White Matter Z-scores measured from PET images taken at 3 months in nasal foralumab treated patients with non-active secondary...Read more


Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes

April 25
Last Trade: 15.02 0.31 2.11

Novel Supplement Shown to Address Signs and Symptoms of Dry Eyes, All Primary Endpoints Achieved VAUGHAN, Ontario / Apr 25, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Frontiers in Ophthalmology published statistically significant results from a clinical study evaluating the efficacy and safety of a novel...Read more


DarioHealth Publishes New Peer-Reviewed Study that Deepens the Body of Evidence that Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes

April 25
Last Trade: 1.76 0.16 10.00

Quasi-randomized study demonstrates the value of Dario's integrated approach to provide one solution for members to manage diabetes, pre-diabetes, blood pressure, weight and taking a GLP-1 NEW YORK, April 25, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today new research published in the leading peer-reviewed journal for digital health and...Read more


Long-term Complete Response to Can-Fite BioPharma's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

April 25
Last Trade: 2.46 0.02 0.82

PETACH TIKVA, Israel / Apr 25, 2024 / Business Wire / Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it published an article in the Experimental and Therapeutic Medicine Journal, titled “Long-term complete response to namodenoson in liver cancer with Child-Pugh B cirrhosis: A case...Read more


Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal

April 24
Last Trade: 1.78 0.07 4.09

  Detailed results from randomized controlled Bentrio® trial in seasonal allergic rhinitis published in Allergy journal Study met primary efficacy endpoint of improvement in nasal symptoms (p = 0.013) Corroborated by statistically significant improvement in health-related quality of life and reduced need for relief medication Study outcomes support plans for further international expansion HAMILTON, BERMUDA -- April 24,...Read more


First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients

April 24
Last Trade: 2.57 0.00 0.00

BOCA RATON, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced research generated from two previously completed Phase 2 clinical trials of latiglutenase has been published in the special issue...Read more


Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

April 23
Last Trade: 1.44 -0.07 -4.63

SOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, and neurological conditions, today announced the publication of an article, “The emerging role of fatty acid binding protein 7 (FABP7) in cancers,” in Drug Discovery Today,...Read more


MindBio Therapeutics Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry

April 23
Last Trade: 0.05 0.00 0.00

MindBio scientist's sleep research published in prestigious peer reviewed scientific journal MindBio's proprietary treatment protocol using MB22001, results in longer sleep and better quality of sleep the day after microdosing VANCOUVER, BC / ACCESSWIRE / April 23, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a clinical stage biopharma company uniquely pioneering novel treatments for...Read more


New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance

April 22
Last Trade: 20.80 -0.04 -0.19

SOUTH SAN FRANCISCO, Calif. / Apr 22, 2024 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that a new study published in JCO Precision Oncology shows that, among patients undergoing Active Surveillance (AS) for prostate cancer, the Decipher Prostate Genomic Classifier is prognostic for identifying those whose disease is likely to progress. The findings make the Decipher test the only...Read more


Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications

April 22
Last Trade: 109.51 2.00 1.86

Demonstrates commitment to generating real-world clinical evidence to change disease management and improve patient outcomes AUSTIN, Texas / Apr 22, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the publication of more than 200 peer-reviewed papers highlighting Natera’s technology in the scientific...Read more


XORTX Therapeutics Announces Publication of Key Research in ADPKD

April 22
Last Trade: 2.58 -0.02 -0.77

CALGARY, Alberta, April 22, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce a research paper titled “Raising serum uric acid with a uricase inhibitor worsens PKD in rat and mouse models" has been accepted for...Read more


Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry

April 18
Last Trade: 0.36 0.0071 2.03

- Publication explores structure-activity relationships (“SAR”) of a broad range of 2C-X analogs - - Innovative research led to the discovery of CYB210010, a potent and long-acting serotonin 5-HT2 receptor agonist with favorable pharmacokinetic properties - TORONTO / Apr 18, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to...Read more


Smith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing’s role in pressure injury prevention  

April 18
Last Trade: 24.87 0.22 0.89

Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology company is pleased to announce exciting data for its ALLEVYN LIFE Dressing in a recent study by Professor Amit Gefen and his research group published in the International Wound Journal,1 that shows a novel mechanism of action relating to pressure injury prevention (PIP). The study found that due to the independent and non-bonded internal layers of ALLEVYN LIFE Dressing, a...Read more


Chemomab Therapeutics Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

April 18
Last Trade: 0.87 0.03 3.68

Longitudinal Study of a 200+ Real-World Patient Cohort Further Validates CCL24 as a Novel Target for Systemic Sclerosis (SSc), Showing that It is Associated with Disease Severity Across the Fibrotic and Vascular Manifestations of SSc TEL AVIV, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare...Read more


Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®

April 17
Last Trade: 12.51 0.06 0.48

The article published in Aesthetic Surgery Journal supports safety and duration of effect for temporary improvement in the appearance of moderate to severe glabellar lines presented at the 2023 ASDS Annual Meeting Data showed duration effect of 26 weeks, or 6 months, based on a ≥ 1-point Glabellar Line Scale (GLS) improvement and return to baseline value using the Global Aesthetic Improvement Scale NEWPORT BEACH, Calif. / Apr 17, 2024...Read more


atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

April 17
Last Trade: 1.61 -0.02 -1.23

BPL-003 is Beckley Psytech’s novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered intranasally. BPL-003 was shown to be safe and well-tolerated with a predictable pharmacokinetic profile and a reliable induction of subjective psychedelic effects with single doses of up to 12 mg in healthy participants. Subjective psychedelic effects correlated with 5-MeO-DMT exposure and had a rapid onset and short...Read more


New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen

April 16
Last Trade: 23.16 -0.11 -0.47

SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Prenatal Diagnosis has published a study1 demonstrating exceptional positive predictive value (PPV) for 22q11.2 microdeletion screening using Myriad’s prenatal cell-free DNA (pcfDNA) screen, Prequel®, which incorporates fetal fraction amplification. Prior studies from other...Read more


Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

April 15
Last Trade: 20.04 -0.06 -0.30

DUBLIN / Apr 15, 2024 / Business Wire / Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced the publication related to the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab, a potential best-in-class anti-amyloid treatment for AL amyloidosis. The publication...Read more


CVRx announces availability of additional data supporting long-term benefits of Barostim

April 15
Last Trade: 7.45 -0.37 -4.73

BeAT-HF trial data published in the European Journal of Heart Failure and new abstracts presented at THT conference MINNEAPOLIS, Minn., April 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today the availability of additional data, including the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of Heart Failure. These...Read more


Can-Fite BioPharma: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

April 15
Last Trade: 2.46 0.02 0.82

A pivotal Phase III trial for advanced liver cancer, approved by FDA & EMA and a MASH Phase IIb are enrolling patients PETACH TIKVA, Israel / Apr 15, 2024 / Business Wire / Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that Biomedicines published an article titled...Read more


Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)

April 15
Last Trade: 0.80 -0.02 -2.52

Paper details vaccine design optimization process of Gritstone’s “off-the-shelf” or shared neoantigen vaccine platform, SLATE  Discovery of a novel immunodominance hierarchy of tumor neoantigens (including KRAS) enabled the development of a more potent, KRAS-specific vaccine candidate (SLATE-KRAS) being studied by Steven A. Rosenberg of the National Cancer Institute (NCI)  Publication underscores the important role of...Read more


Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation

April 11
Last Trade: 109.51 2.00 1.86

ProActive study shows Natera’s Prospera Kidney™ test detects rejection five months before biopsy AUSTIN, Texas / Apr 11, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting the use of the Prospera Kidney donor-derived cfDNA (dd-cfDNA) test as a leading indicator of kidney transplant rejection. The...Read more


Bionano Genomics Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing

April 11
Last Trade: 1.07 0.04 3.88

SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study from Penn State College of Medicine that used optical genome mapping (OGM) to search for clinically and biologically relevant genomic variations in pediatric B-cell acute lymphoblastic leukemia (B-ALL). The study also used whole genome sequencing (WGS) for variant detection and evaluated the two approaches...Read more


Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

April 11
Last Trade: 0.44 -0.02 -4.09

Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 women Pivotal Phase 3 contraceptive efficacy clinical study of Ovaprene currently enrolling Ovaprene has the potential to be the first FDA-approved hormone-free monthly intravaginal contraceptive for women SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation,...Read more


Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease

April 11
Last Trade: 2.64 0.08 3.12

BOTHELL, Wash., April 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the publication of preclinical data supporting the therapeutic potential of fosgonimeton in Alzheimer’s disease. The original research article, “Fosgonimeton Attenuates Amyloid-Beta Toxicity in...Read more


Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs

April 10
Last Trade: 2.82 -0.08 -2.76

NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy, demonstrating that TALEN-mediated intron editing of hematopoietic stem and progenitor cells (HSPCs) enables transgene...Read more


Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications...

April 10
Last Trade: 5.57 0.29 5.49

MENLO PARK, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced the results as published in the American Journal of Ophthalmology (“AJO”) International of the large scale, comparative real-world...Read more


Neuronetics: New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital

April 10
Last Trade: 2.18 -0.12 -5.22

MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced the publication of significant clinical findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation, the premier journal in the...Read more


DarioHealth Publishes Two New Peer-Reviewed Studies Demonstrating Impact of Digital Behavioral Health

April 10
Last Trade: 1.76 0.16 10.00

Studies include a Randomized Controlled Trial demonstrating significant reduction in perceived stress for teens NEW YORK, April 10, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new studies published in the leading peer-reviewed journal for digital health and medicine, Journal of Internet Medicine (JMIR), including a Randomized...Read more


Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

April 10
Last Trade: 1.25 0.00 0.00

GLEN ALLEN, Va., April 10, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the publication of a peer-reviewed article highlighting the promising clinical results, strong safety profile and high compliance among patients administered AD04...Read more


BrainStorm Cell Therapeutics Announces Peer-Reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS

April 10
Last Trade: 0.54 -0.04 -7.04

NurOwn treatment resulted in a positive impact on important CSF biomarkers relevant to ALS compared to placebo. Significant changes in multiple ALS disease pathways support NurOwn's mechanism of action and complement clinical effects observed in ALS. NEW YORK, April 10, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the...Read more


Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

April 9
Last Trade: 37.95 -0.18 -0.47

REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the publication of a peer-reviewed research paper in Cancer Discovery. The scientific paper details the discovery and preclinical to clinical translation for RMC-6236, an investigational RAS(ON) multi-selective inhibitor,...Read more


ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

April 9
Last Trade: 1.75 0.07 3.88

CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 09, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc.(Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced the publication of supportive preclinical...Read more


Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

April 8
Last Trade: 37.95 -0.18 -0.47

Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS(ON) multi-selective tri-complex inhibitor that exhibits unprecedented anti-tumor activity in preclinical models of RAS-mutant pancreatic ductal adenocarcinoma (PDAC) First paper demonstrates RMC-7977 successfully targets signaling by both mutant and wild-type forms of RAS to drive potent and durable inhibition of RAS-mutated...Read more


Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

April 8
Last Trade: 2.32 0.01 0.43

JERUSALEM, April 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today that data from the Phase 2 Trial of its lead clinical compound, EB613 (Oral PTH(1-34) Tablets) for the Treatment of Post-Menopausal Women with Low BMD or Osteoporosis compared to placebo were published in the Journal of Bone and Mineral Research (JBMR). Miranda...Read more


Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients

April 8
Last Trade: 109.51 2.00 1.86

Prospective, multi-center Trifecta-Heart and DTRT-2 studies demonstrate excellent performance of the Prospera Heart test for detecting rejection in adults and pediatrics AUSTIN, Texas / Apr 08, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of two major studies, DTRT-2 and Trifecta-Heart, showcasing the ability of the Prospera Heart donor-derived...Read more


Bio-Techne Surpasses 10,000 Peer-Reviewed Publications Citing RNAScope Technology

April 8
Last Trade: 80.79 0.38 0.47

Advanced Cell Diagnostics (ACD) achieves significant global customer adoption milestone MINNEAPOLIS, April 8, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology Division, has surpassed 10,000 peer-reviewed publications referencing the use and application of RNAscope™ ISH technology. Over 50% of these publications were released in the past 3...Read more


Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

April 4
Last Trade: 0.79 -0.66 -45.52

BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the publication of a peer-reviewed research paper in Nature Communications. The research was conducted by scientists at Sensei Biotherapeutics in collaboration with genOway and the laboratory of Dr....Read more


Rigel Pharmaceuticals Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma

April 4
Last Trade: 0.91 0.0044 0.49

Olutasidenib induced durable composite complete remission in 43.8% of patients relapsed or refractory to prior venetoclax-based regimens Safety was consistent with the overall profile of olutasidenib Olutasidenib may offer a valuable treatment option for patients with mIDH1 previously treated with venetoclax SOUTH SAN FRANCISCO, Calif., April 4, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a...Read more


Tempest Therapeutics Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

April 4
Last Trade: 3.25 0.04 1.09

TPST-1120, a first-in-class, oral, selective PPAR⍺ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancers Based on subsequent positive randomized data, Company preparing to move TPST-1120 into pivotal Phase 3 trial in HCC BRISBANE, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi...Read more


BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's Disease

April 4
Last Trade: 5.40 0.05 0.93

JERUSALEM and BURLINGTON, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced results published in a review article exploring the potential efficacy of Deep Transcranial Magnetic Stimulation (Deep TMS™) as a novel therapeutic approach for Parkinson's Disease (PD). The...Read more


ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes

April 4
Last Trade: 4.31 0.02 0.46

Atherosclerosis (AS) and its sequelae are the most common cause of death in diabetic patients and one of the reasons why diabetes has entered the top 10 causes of death worldwide. The published data show that inhibiting the NLRP3 inflammasome pathway significantly reduces atherosclerotic lesions and improves hyperglycemic-induced plaque instability. ZyVersa is developing IC 100, a monoclonal antibody targeting inflammasome ASC and ASC...Read more


Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections

April 4
Last Trade: 0.20 0.0083 4.39

BOULDER, CO / ACCESSWIRE / April 4, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions and podiatry, reported a recent publication in the journal Neurourology and Urodynamics highlighting the potential for...Read more


HEALWELL AI’s Pentavere Achieves Validation of Generative AI for Preventative Care Through Landmark Publication

April 4
Last Trade: 1.72 0.00 0.00

Pentavere has published industry’s first peer-reviewed paper utilizing AI and large language models (or LLMs) to identify rare lung cancer patients. Industry applications may include Real World Evidence generation, identification of areas of unmet clinical need and optimization of cancer therapy and care pathways. Pentavere is an AI-powered patient identification company and this validated instance of identifying cancer patients using...Read more


Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature

April 3
Last Trade: 166.61 2.60 1.59

CAMBRIDGE, MA / ACCESSWIRE / April 3, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that interim data for a first-in-human, phase 1/2, open-label, dose optimization study and extension study, evaluating the safety and efficacy of mRNA-3927, an investigational mRNA therapy for propionic acidemia (PA), has been published in Nature. "We are excited to share the first published clinical data utilizing an mRNA therapy for intracellular...Read more


Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

April 3
Last Trade: 10.45 0.16 1.55

In a preclinical model of pulmonary fibrosis, a Surrozen antibody-based SWAP platform molecule decreased pulmonary inflammation and fibrosis and improved lung function Surrozen Wnt mimetic SWAP molecules also expanded alveolar organoid cultures and impacted multiple lung cell types in vivo Results highlight the potential of Wnt mimetic agonists to repair tissue after damage in severe lung diseases like idiopathic pulmonary...Read more


Bionano Genomics Announces Publication Showing that OGM Identifies Genetic Aberrations in Sarcoma Samples that May Lead to Improved Diagnosis but were Missed by Classical Cytogenetics

April 3
Last Trade: 1.07 0.04 3.88

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a peer-reviewed study that compared optical genome mapping (OGM) to classical cytogenetic techniques used for analysis of solid tumor cancer samples consisting of soft tissue and bone sarcomas, including fluorescence in situ hybridization (FISH) and karyotyping (KT). OGM demonstrated high levels of concordance with...Read more


First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med

March 29
Last Trade: 13.00 0.00 0.00

Two patients were treated with KYV-101, a fully human anti-CD19 CAR T-cell product candidate, in Germany as part of a named patient program after failure to respond to conventional therapies The treatment resulted in an acceptable safety profile, with no observed clinical signs of early neurotoxicity, warranting larger clinical studies in subjects with multiple sclerosis EMERYVILLE, Calif., March 29, 2024 /PRNewswire/...Read more


BrainsWay Announces Positive Results in Late-Life Depression Post-Marketing Analysis

March 28
Last Trade: 5.40 0.05 0.93

JERUSALEM and BURLINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced positive results in a recently published post-marketing study of its Deep Transcranial Magnetic Stimulation (Deep TMS™) for the treatment of late-life depression. The data were highlighted in...Read more


REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD

March 28
Last Trade: 14.92 -0.04 -0.27

A single ABBV-RGX-314 gene therapy treatment has the potential to become a new standard-of-care option among anti-VEGF treatments by sustaining vision health long term and overcoming the clinical challenges of managing wet AMD due to the treatment burden of chronic anti-VEGF injections Patients who received therapeutic doses resulted in stable or improved vision and retinal anatomy up to 2 years Additional long-term follow-up data has...Read more


Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer

March 28
Last Trade: 49.84 -4.24 -7.84

Results indicate potential of a minimally invasive screening tool to detect most common form of Esophageal Cancer, a highly treatable cancer if caught early MADISON, Wis. / Mar 28, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, in collaboration with Mayo Clinic Comprehensive Cancer Center, reported on data showing high sensitivity and specificity for the...Read more


Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

March 27
Last Trade: 1.05 0.04 3.96

Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that The Lancet published the company's pivotal Phase 2 data with afami-cel. The article, titled "SPEARHEAD-1: a single-arm phase 2 trial of afamitresgene autoleucel (afami-cel) in advanced synovial sarcoma and...Read more


New Scientific Publication Shows LB-100, Lixte’s Lead Clinical Compound, Can Force Cancer Cells To Give Up Their Cancer-Causing Properties

March 27
Last Trade: 2.43 0.04 1.63

LB-100 IS SYNERGISTIC WITH WEE1 INHIBITION IN KILLING CANCER CELLS; FINDING OPENS NEW TREATMENT STRATEGY IN ADDITION TO THREE CURRENT LIXTE CLINICAL TRIALS PASADENA, CA, March 27, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, announced today publication of pre-clinical data in the online journal, Cancer Discovery, showing that...Read more


Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications

March 26
Last Trade: 1.95 0.25 14.71

The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhuman primate models compared to monoclonal antibody produced in CHO. JUPITER, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms today announced the...Read more


Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease

March 26
Last Trade: 141.28 1.24 0.89

Findings suggest the test can reduce the need for PET imaging in some patients with mild cognitive decline to enable therapeutic focus on non-Alzheimer's disease causes, broadening access to quality evaluation and lowering healthcare costs SECAUCUS, N.J., March 26, 2024 /PRNewswire/ -- A blood test that analyzes levels of amyloid proteins by highly sensitive mass spectrometry could help physicians establish that Alzheimer's disease...Read more


United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation

March 26
Last Trade: 272.88 -3.62 -1.31

Review manuscript available in the journal Physiological Reviews SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Mar 26, 2024 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the online availability of a review manuscript titled “Physiological Basis for Xenotransplantation from Genetically-Modified Pigs to Humans: A Review,” in the journal Physiological Reviews. The...Read more


Sign Up To Get Daily Life Science Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

COPYRIGHT ©2023 HEALTH STOCKS HUB